NLS Ebitda from 2010 to 2024

NLSPW Stock  USD 0.02  0.0001  0.62%   
NLS Pharmaceutics EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA will likely drop to about -12.4 M in 2024. During the period from 2010 to 2024, NLS Pharmaceutics EBITDA regression line of quarterly data had r-squared of  0.36 and coefficient of variation of (52.03). View All Fundamentals
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
-11.8 M
Current Value
-12.4 M
Quarterly Volatility
3.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check NLS Pharmaceutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NLS Pharmaceutics' main balance sheet or income statement drivers, such as Interest Income of 681.3 K, Depreciation And Amortization of 9.8 K or Interest Expense of 137.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NLS financial statements analysis is a perfect complement when working with NLS Pharmaceutics Valuation or Volatility modules.
  
Check out the analysis of NLS Pharmaceutics Correlation against competitors.

Latest NLS Pharmaceutics' Ebitda Growth Pattern

Below is the plot of the Ebitda of NLS Pharmaceutics AG over the last few years. It is NLS Pharmaceutics' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NLS Pharmaceutics' overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

NLS Ebitda Regression Statistics

Arithmetic Mean(7,214,061)
Coefficient Of Variation(52.03)
Mean Deviation3,019,517
Median(5,766,724)
Standard Deviation3,753,635
Sample Variance14.1T
Range13.2M
R-Value(0.60)
Mean Square Error9.8T
R-Squared0.36
Significance0.02
Slope(500,468)
Total Sum of Squares197.3T

NLS Ebitda History

2024-12.4 M
2023-11.8 M
2022-15.5 M
2021-11.9 M
2020-2.3 M
2019-4.2 M
2018-4.1 M

About NLS Pharmaceutics Financial Statements

NLS Pharmaceutics investors use historical fundamental indicators, such as NLS Pharmaceutics' Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NLS Pharmaceutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA-11.8 M-12.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NLS Stock Analysis

When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.